Characteristics, incidence, risk factors, and practical management of pneumonitis associated with anti-PD-1 immunotherapy in patients with non-small cell lung cancer

M. Moda (Kanagawa, Japan)

Source: International Congress 2019 – Treatment of lung cancer
Session: Treatment of lung cancer
Session type: Poster Discussion
Number: 366
Disease area: Thoracic oncology

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
M. Moda (Kanagawa, Japan). Characteristics, incidence, risk factors, and practical management of pneumonitis associated with anti-PD-1 immunotherapy in patients with non-small cell lung cancer. 366

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Incidence, predictors and prognostic significance of thromboembolic disease in patients with advanced ALK-rearranged non-small cell lung cancer
Source: Eur Respir J, 51 (5) 1702431; 10.1183/13993003.02431-2017
Year: 2018



Lung cancer: does age affect treatment strategy?
Source: Eur Respir Mon; 2009: 43:306–326
Year: 2009

Prevalence and effectiveness of third-line therapy for advanced non-small cell lung cancer (A-NSCLC)
Source: Annual Congress 2012 - Treatment of lung cancer
Year: 2012


Clonality of multifocal nonsmall cell lung cancer: implications for staging and therapy
Source: Eur Respir J 2012; 39: 1437-1442
Year: 2012



Treatment of extensive-stage small cell lung carcinoma: current status and future prospects
Source: Eur Respir J 2010; 35: 202-215
Year: 2010



Customising chemotherapy in advanced nonsmall cell lung cancer: daily practice and perspectives
Source: Eur Respir Rev 2011; 20: 45-52
Year: 2011



Efficacy of local therapy for oligoprogressive disease after PD-1 blockade in advanced non-small cell lung cancer
Source: Virtual Congress 2021 – COVID-19 and management of lung cancer
Year: 2021


Predictors of major serious manifestations in the terminal stage of lung cancer
Source: Annual Congress 2005 - Management of lung cancer: clinical problems
Year: 2005


Impact of COPD on prognosis of lung cancer: the prespective of immunotherapy treatment
Source: Virtual Congress 2021 – Therapy of lung cancer
Year: 2021


Epidemiological and clinical predictors of survival during the first year of the treatment in non-small cell lung cancer patients
Source: Annual Congress 2009 - Treatment of lung cancer
Year: 2009

Lazarus syndrome in nonsmall cell lung cancer patients with poor performance status and major leukocytosis following nivolumab treatment
Source: Eur Respir J, 50 (1) 1700310; 10.1183/13993003.00310-2017
Year: 2017



The influence of secondary infectious process on non-small cell lung cancer (NSCLC) patients survival
Source: Eur Respir J 2007; 30: Suppl. 51, 280s
Year: 2007

Clinical characteristics, treatment, and prognosis of lung cancer elderly patients
Source: Eur Respir J 2001; 18: Suppl. 33, 228s
Year: 2001

Impacts of multi and specific co-morbidities on the survival of non-surgical non-small cell lung cancer
Source: Annual Congress 2012 - Prognosis of lung cancer
Year: 2012

Symptoms, signs and staging of lung cancer
Source: ISSN=1025-448x, ISBN=1-904097-18-9, page=86
Year: 2001

Chemotherapy improves low performance status lung cancer patients
Source: Eur Respir J 2007; 30: 1186-1192
Year: 2007



Impact of radiotherapy on outcomes of nivolumab in advanced non-small cell lung cancer: a case controlled study
Source: International Congress 2018 – Lung cancer: personalised medicine
Year: 2018




Assessment of lung cancer related symptoms and chemotherapy related side effects in a group of patients with advanced lung cancer receiving palliative chemotherapy
Source: Eur Respir J 2006; 28: Suppl. 50, 752s
Year: 2006

Characterization and management of elderly and very elderly patients with non-small cell lung cancer
Source: International Congress 2018 – Lung cancer: modern therapies and beyond
Year: 2018